Waiting for Multi-Stakeholders’Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature

참고문헌 (9)

1. Moon Joon Ho, "Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease", Gut and Liver, 16(3), pp.433~442 (2022), 거트앤리버 소화기연관학회협의회[DOI]
2. Han Eugene, "Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 16(5), pp.786~797 (2022), 거트앤리버 소화기연관학회협의회[DOI]
3. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
4. Park H, "Fibrosis burden of missed and added populations according to the new definition of metabolic dysfunction-associated fatty liver", J Clin Med, 10, pp.4625~ (2021)
5. Lee YB, "Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B", Hepatology, 73, pp.2266~2277 (2021)
6. Eslam M, "MAFLD : a holistic view to redefining fatty liver disease", J Hepatol, 74, pp.983~985 (2021)
7. Mimi Kim, "Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea", Liver International, 42(7), pp.1536~1544 (2022), Wiley[DOI]
8. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness : the Rotterdam Study", Hepatology, 75, pp.419~429 (2022)
9. Park H, "Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease", Gut, 71, pp.1035~1036 (2022)

관련 논문AI추천